Home > Boards > US Listed > Biotechs > Can-Fite BioPharma (CANF)

Can-Fite announces final data from mid-stage study of

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
midastouch017 Member Profile
 
Followed By 109
Posts 24,068
Boards Moderated 14
Alias Born 02/07/04
160x600 placeholder
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/30/2020 7:08:57 AM
Can-Fite Announces Final Data Analysis from Phase II NASH Study: Business Wire - 6/30/2020 7:00:00 AM
Small Company Offering and Sale of Securities Without Registration (d) Edgar (US Regulatory) - 6/19/2020 4:36:29 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 6/19/2020 4:24:38 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 6/19/2020 6:03:47 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/12/2020 8:30:54 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/12/2020 8:04:03 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/10/2020 8:11:22 AM
Can-Fite Announces $8.0 Million Registered Direct Offering Business Wire - 6/10/2020 8:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/9/2020 7:05:20 AM
Following Pre-IND Guidance from FDA Can-Fite to Advance Piclidenoson into Phase II COVID-19 Trial in the U.S. Business Wire - 6/9/2020 7:00:00 AM
Can-Fite Participating in BIO Digital International Convention and One-on-One Partnering Meetings on June 8-12, 2020 Business Wire - 6/8/2020 7:25:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/4/2020 7:22:28 AM
Can-Fite Concludes Successful Meeting with European Medicines Agency (EMA) Regarding Phase III Trial & Registration Plan for ... Business Wire - 6/4/2020 7:14:00 AM
Can-Fite BioPharma to Hold Investor Webinar and Q&A Session with CEO on June 4th Business Wire - 6/3/2020 7:00:00 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 6/1/2020 7:24:12 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/1/2020 7:07:32 AM
Can-Fite Reports First Quarter 2020 Financial Results & Provides Clinical Update Business Wire - 6/1/2020 7:00:00 AM
Can-Fite to Host First Quarter 2020 Financial Results & Clinical Update Conference Call on June 1, 2020 Business Wire - 5/28/2020 7:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/21/2020 7:13:58 AM
Can-Fite Receives Notice of Allowance for Namodenoson Patent in the Treatment of NASH & NAFLD from U.S. Patent & Trademark Of... Business Wire - 5/21/2020 7:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/18/2020 7:09:21 AM
Can-Fite Reports Additional Findings from Successful Phase II NASH Study: 25 mg Dose of Namodenoson Significantly Reduced Liv... Business Wire - 5/18/2020 7:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/15/2020 7:29:18 AM
Can-Fite Announces Pre-IND Submission to U.S. FDA for Piclidenoson in the Treatment of COVID-19 Infected Patients with Modera... Business Wire - 5/15/2020 7:00:00 AM
midastouch017   Tuesday, 06/30/20 07:43:51 AM
Re: midastouch017 post# 1444
Post # of 1449 
Can-Fite announces final data from mid-stage study of Namodenoson in NASH

Jun. 30, 2020 7:39 AM ET|About: Can-Fite BioPharma Ltd. (CANF)|By: Douglas W. House, SA News Editor

Can-Fite BioPharma (NYSEMKT:CANF) reports the final analysis of results from a 60-subject Phase 2 clinical trial evaluating Namodenoson (formerly CF102) in patients with nonalcoholic fatty liver disease (NAFLD) with or without nonalcoholic steatohepatitis (NASH).

The 25 mg oral dose produced statistically significant results in all efficacy measures while being safe and well-tolerated.

Liver fat volume decreased the most in the 25 mg arm (102.1 - unit of measurement not provided) compared to placebo (33.0) (p=0.027).

The percent decrease in fat volume in the 25 mg arm was 4.33% versus 2.61% in the control arm (p=0.036).

Levels of two key liver enzymes, AST and ALT, were significantly reduced as was liver fibrosis and steatosis (25 mg).

All cases of NASH resolved in the 25 mg arm.

Phase 3 studies are next up.

https://seekingalpha.com/news/3587259-can-fite-announces-final-data-from-mid-stage-study-of-namodenoson-in-nash?utm_medium=email&utm_source=seeking_alpha&mail_subject=canf-can-fite-announces-final-data-from-mid-stage-study-of-namodenoson-in-nash&utm_campaign=rta-stock-news&utm_content=link-3

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist